Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Johnson and Johnson...

    Johnson and Johnson wins appeal to overturn 151 million dollar hip implant verdict

    Written by Ruby Khatun Khatun Published On 2018-04-26T09:45:37+05:30  |  Updated On 26 April 2018 9:45 AM IST
    Johnson and Johnson wins appeal to overturn 151 million dollar hip implant verdict

    Johnson and Johnson secured a favorable U.S. appellate court ruling, overturning a verdict that had awarded $151 million to five people who blamed injuries they suffered on the company’s Pinnacle hip implant devices.


    The 5th U.S. Circuit Court of Appeals said two of the plaintiffs’ defective marketing claims were legally insufficient and a new trial was required overall in the case because of a judge’s evidentiary rulings and “deceptions” by their lawyer.


    U.S. Circuit Judge Jerry Smith, writing for the three-judge panel, said U.S. District Judge Ed Kinkeade in Dallas erred in allowing the hip implant recipients’ lawyers to present certain “inflammatory character evidence” about J&J.


    Smith said the “most problematic evidence” were bribes J&J paid to “henchmen” of Saddam Hussein in Iraq, allegations stemming from the company’s agreement in 2011 to pay $70 million to resolve U.S. foreign bribery probes.


    “Because the taint is unmistakable, the verdict cannot stand,” Smith wrote.


    He also said two of the plaintiffs, Donald Greer and Robert Peterson, had presented no evidence suggesting the doctors who treated them had even encountered the allegedly inadequate warnings the company issued about Pinnacle’s risks.


    Smith said “falsehoods” that the plaintiffs’ lead lawyer, Mark Lanier, made at trial about whether two doctors were compensated to testify as experts had also “marred plaintiffs; victory.”


    Lanier said he believed the court “misunderstood” the issues but would not appeal and would seek a retrial as quickly as possible.


    John Beisner, a lawyer for J&J and its DePuy unit, said the ruling “makes clear, the trial was rife with errors that made it impossible for defendants to get a fair trial.” He said he looked forward to a retrial on a “level playing field.”


    DePuy ceased selling the metal-on-metal Pinnacle devices in 2013 after the U.S. Food and Drug Administration strengthened its artificial hip regulations.


    The Pinnacle devices are now the subject of around 10,000 product liability lawsuits, according to J&J.


    The case at issue was a so-called bellwether, or test, trial aimed at allowing the parties to gauge the value of the remaining claims and inform potential settlement talks.


    A federal jury in Dallas awarded five plaintiffs - Greer, Peterson, Margaret Aoki, Jay Christopher, and Richard Klusmann -$502 million in March 2016.


    Kinkeade later reduced the award to $151 million.




    DePuy prevailed in one other federal trial but was hit in two others with verdicts worth $543 million, after a post-trial reduction, and $247 million.




    (Reporting by Nate Raymond in Boston; Editing by Himani Sarkar)




    appealDePuyhip implantJohnson and JohnsonPinnacleproduct liability lawsuitsU.S. Food and Drug Administrationverdictwins
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok